Hafnia alvei impact on regulation of appetite and metabolic syndrome aspects
US11369645B2 · kind B2 · utility
0Cited by
0References
8Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 16, 2020 |
| Grant date | Jun 28, 2022 |
| Priority date | — |
| Expiry date | Jun 16, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2035/115
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to method of preventing, treating or attenuating obesity-related manifestations in a human or non-human mammal subject in need thereof, said method comprising orally administering to the subject a composition comprising an effective amount Hafnia alvei probiotics; wherein said obesity-related parameters are selected from the group of hyperphagia, increased fat mass on lean mass ratio, increased waist circumference, postprandial hyperglycemia, fasting hyperglycemia and hypercholesterolemia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.